Furthermore, the incidence of grade 3 or higher hyperglycaemia, defined as the initiation of insulin therapy according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, was lower in imatinib-treated patients (11% vs. 20%, Chi-squared test p = 0.022). This evidence concerns the gene INS and Hyperglycemia.